Terconazole Repurposing for Bladder Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bladder cancer, including those recurring post-BCG treatment, often come with severe side effects and inadequate efficacy, necessitating the development of more effective and less toxic therapeutic options.
Innovation Solution
Administration of terconazole, either alone or in combination with other anti-cancer agents, to target angiogenesis pathways and modulate oxidative stress in bladder cancer cells, thereby inhibiting tumor growth and metastasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard chemotherapies (MVAC, GC) are administered to treat bladder cancer, then tumor growth is inhibited, but severe negative side effects occur
Solution Approach 1:
The patent changes the chemical parameter from conventional chemotherapeutic agents (MVAC, GC) to terconazole, an antifungal agent with repurposed anticancer activity. This parameter change allows achieving tumor growth inhibition while reducing the severity of side effects, as terconazole demonstrates a more favorable toxicity profile compared to standard chemotherapy regimens
2Reliability
If BCG immunotherapy is administered to prevent bladder cancer recurrence, then immune reaction clears residual cancer cells, but recurring cancer becomes more difficult to treat
Solution Approach 1:
The patent positions terconazole as an intermediary treatment option for bladder cancer patients who have failed BCG immunotherapy. Terconazole provides an alternative mechanism of action that is effective against BCG-resistant recurrent tumors, thereby expanding treatment versatility without compromising recurrence prevention capabilities
3Reliability
If surgery (TURBT, cystectomy) is performed to remove bladder cancer, then cancerous cells are removed, but recurrence concerns require additional chemotherapy or immunotherapy
Solution Approach 1:
The patent extracts the essential function of adjuvant therapy (preventing recurrence) and achieves it through a simplified approach. By using terconazole, which can be administered intravesically with simple instillation and drainage procedures, the complex multi-agent chemotherapy or immunotherapy regimens are replaced with a single, easier-to-administer agent that maintains effective recurrence prevention
Data Source
AI summary
Methods of treating bladder cancer using terconazole are disclosed herein. Terconazole can be administered as part of a comprehensive treatment program, which can also include chemotherapy, immunotherapy, radiation therapy and/or surgical treatment.